Black Diamond Therapeutics, Inc. last reported quarterly results on Aug 5, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $0 and diluted EPS of -$0.17. It usually reports 36–75 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–75 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
|
-10
+6.2%
|
-0.17
+10.5%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
-100.0%
|
-9
-116.0%
|
-0.16
-116.3%
|
|
Mar 16, 2026
75 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
|
-15
+5.4%
|
-0.26
+7.4%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
|
-8
+45.4%
|
-0.15
+46.4%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
|
-11
+47.0%
|
-0.19
+47.2%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
70
|
57
+410.2%
|
0.98
+380.0%
|
|
Mar 6, 2025
65 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-16
+17.6%
|
-0.28
+24.9%
|
|
Nov 5, 2024
36 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-16
+32.4%
|
-0.28
+37.8%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BDTX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1701541
- Former names
- Aset Therapeutics, Inc. (until Jan 4, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.